The next wave of Duchenne trials
Our May 2026 whitepaper: The Next Wave of Duchenne Trials.
2026 is shaping up to be the most significant year in Duchenne muscular dystrophy research in decades — with 5+ BLA submissions expected from Avidity, Dyne, REGENXBIO, Wave Life Sciences, and Capricor. The bottleneck isn't science. It's sites.
Our paper makes the case for Armenia, Georgia, Ukraine, and Uzbekistan — 75M people, 1,400+ modeled DMD patients, largely treatment-naïve — as a credible and operational part of the solution.
Sign up to read this post
Join Now